Catalyst Pharmaceuticals defends $375,000 drug price after Bernie Sanders rebuke

By Manas Mishra (Reuters) - Catalyst Pharmaceuticals Inc, rebuked by U.S. Senator Bernie Sanders for its high drug prices, on Thursday defended its $375,000 treatment for a rare disease, saying the price was in line with similar products in the industry. Sanders, a vocal critic of high drug prices, had written to Florida-based Catalyst earlier this month, asking it to justify its price for Firdapse, a medication for a rare neuromuscular disease that affects about one in 100,000 people in the United States.

Reuters February 22, 2019 02:05:31 IST
Catalyst Pharmaceuticals defends $375,000 drug price after Bernie Sanders rebuke

Catalyst Pharmaceuticals defends 375000 drug price after Bernie Sanders rebuke

By Manas Mishra

(Reuters) - Catalyst Pharmaceuticals Inc, rebuked by U.S. Senator Bernie Sanders for its high drug prices, on Thursday defended its $375,000 treatment for a rare disease, saying the price was in line with similar products in the industry.

Sanders, a vocal critic of high drug prices, had written to Florida-based Catalyst earlier this month, asking it to justify its price for Firdapse, a medication for a rare neuromuscular disease that affects about one in 100,000 people in the United States.

Drug pricing has been a major talking point in the US for the past few years. It was also one of the campaign promises made by President Donald Trump in the 2016 elections. However, healthcare costs have not gone down significantly.

Last month, the Trump administration proposed a rule to overhaul the industry's system of rebates, or discounts, while Sanders unveiled legislation aimed at lowering drug prices.

For years, patients were able to get Firdapse for free from Jacobus Pharmaceuticals, a small New Jersey-based drug company that offered the drug through a U.S. Food and Drug Administration (FDA) program called Compassionate Use.

The program allows patients with rare diseases and conditions access to drugs not yet approved outside of a clinical trial, when there is no viable alternative.

Catalyst bought the U.S. rights to the drug in 2012 and got approval to sell it in the US in November last year.

Sanders said in a statement provided to Reuters on Thursday that Catalyst had shown a "blatant disregard for patients with LEMS (Lambert-Eaton Myasthenic Syndrome)" who he said were already rationing their medication because of the high price-tag.

"I will ask FDA Commissioner Gottlieb to act immediately to help patients who are suffering," said Sanders, who is seeking the Democratic Party's presidential nomination in 2020.

The company said, before its November approval, only about 200 of an estimated 3,000 LEMS patients in the US received some form of Firdapse, pointing to a large unmet medical need.

"Now, for the first time, LEMS patients have confidence their therapy is FDA approved and is safe and effective," Catalyst's Chief Executive Officer Patrick McEnany said in a letter (https://bit.ly/2NkmIRU).

The company said that Firdapse's price was similar to other medicines that provide a significant clinical benefit in treating ultra-rare diseases, adding it believed the drug would be widely reimbursed by insurers for the small population it treats.

(Reporting by Manas Mishra and Aakash Jagadeesh Babu in Bengaluru and Yasmeen Abutaleb in Washington; Editing by Arun Koyyur and Sweta Singh)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date:

TAGS:

Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.

also read

Putin says he has noted Joe Biden's harsh anti-Russian rhetoric
World

Putin says he has noted Joe Biden's harsh anti-Russian rhetoric

MOSCOW (Reuters) - Russian President Vladimir Putin said on Wednesday he had noted what he called "sharp anti-Russian rhetoric" from U.S. Democratic presidential candidate Joe Biden, but that he had been encouraged by Biden's comments on arms control. Putin, in comments on state television ahead of the U.S.

In hardening stance, France, Germany push for EU sanctions on Russians over Navalny
World

In hardening stance, France, Germany push for EU sanctions on Russians over Navalny

By John Irish and Robin Emmott PARIS/BRUSSELS (Reuters) - France and Germany said on Wednesday they would propose European Union sanctions against Russian individuals after receiving no credible answers from Moscow over the poisoning of Kremlin critic Alexei Navalny with a nerve agent. Several Western governments have said Russia, which has denied accusations by Navalny that it was involved in the poisoning, must help in investigations or face consequences. The decision and speed with which Europe's two main powers agreed to push ahead with sanctions suggests a hardening of the bloc's diplomacy towards Moscow.

Coronavirus patient Trump seeks ways to mount campaign comeback
World

Coronavirus patient Trump seeks ways to mount campaign comeback

By Steve Holland WASHINGTON (Reuters) - U.S. President Donald Trump, under coronavirus quarantine in the White House and restricted from traveling, is seeking ways to put a spark back in his struggling re-election bid and get behind his desk in the Oval Office with four weeks left until Election Day.